A detailed history of Voya Investment Management LLC transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 36,438 shares of PLRX stock, worth $484,625. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,438
Previous 36,730 0.79%
Holding current value
$484,625
Previous $394,000 3.55%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.52 - $14.35 $3,071 - $4,190
-292 Reduced 0.79%
36,438 $408,000
Q2 2024

Dec 03, 2024

BUY
$10.58 - $15.61 $3,089 - $4,558
292 Added 0.8%
36,730 $394,000
Q2 2024

Aug 14, 2024

SELL
$10.58 - $15.61 $20,747 - $30,611
-1,961 Reduced 5.07%
36,730 $394,000
Q1 2024

Dec 06, 2024

BUY
$14.14 - $19.59 $31,857 - $44,136
2,253 Added 6.18%
38,691 $576,000
Q1 2024

May 15, 2024

SELL
$14.14 - $19.59 $51,285 - $71,052
-3,627 Reduced 8.57%
38,691 $576,000
Q4 2023

Feb 14, 2024

BUY
$12.85 - $19.15 $3,212 - $4,787
250 Added 0.59%
42,318 $766,000
Q3 2023

Nov 14, 2023

BUY
$14.58 - $20.15 $4,825 - $6,669
331 Added 0.79%
42,068 $729,000
Q2 2023

Aug 14, 2023

BUY
$18.12 - $30.56 $65,087 - $109,771
3,592 Added 9.42%
41,737 $756,000
Q1 2023

May 15, 2023

BUY
$18.73 - $36.26 $714,455 - $1.38 Million
38,145 New
38,145 $1.01 Million
Q3 2021

Nov 15, 2021

SELL
$16.48 - $28.98 $163,234 - $287,046
-9,905 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$28.05 - $37.69 $12,145 - $16,319
-433 Reduced 4.19%
9,905 $288,000
Q1 2021

May 17, 2021

BUY
$24.52 - $40.23 $253,487 - $415,897
10,338 New
10,338 $407,000

Others Institutions Holding PLRX

About PLIANT THERAPEUTICS, INC.


  • Ticker PLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,682,000
  • Market Cap $647M
  • Description
  • Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...
More about PLRX
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.